"Cardiovascular Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Descriptor ID |
D002318
|
| MeSH Number(s) |
C14
|
| Concept/Terms |
Cardiovascular Diseases- Cardiovascular Diseases
- Cardiovascular Disease
- Disease, Cardiovascular
- Diseases, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Diseases".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Diseases".
This graph shows the total number of publications written about "Cardiovascular Diseases" by people in this website by year, and whether "Cardiovascular Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 4 | 2 | 6 |
| 2001 | 3 | 3 | 6 |
| 2002 | 8 | 2 | 10 |
| 2003 | 8 | 6 | 14 |
| 2004 | 8 | 4 | 12 |
| 2005 | 13 | 6 | 19 |
| 2006 | 6 | 9 | 15 |
| 2007 | 11 | 8 | 19 |
| 2008 | 17 | 7 | 24 |
| 2009 | 17 | 4 | 21 |
| 2010 | 13 | 9 | 22 |
| 2011 | 18 | 10 | 28 |
| 2012 | 18 | 9 | 27 |
| 2013 | 20 | 8 | 28 |
| 2014 | 26 | 5 | 31 |
| 2015 | 21 | 5 | 26 |
| 2016 | 19 | 6 | 25 |
| 2017 | 21 | 6 | 27 |
| 2018 | 25 | 6 | 31 |
| 2019 | 32 | 5 | 37 |
| 2020 | 30 | 5 | 35 |
| 2021 | 31 | 10 | 41 |
| 2022 | 27 | 0 | 27 |
| 2023 | 34 | 2 | 36 |
| 2024 | 19 | 8 | 27 |
| 2025 | 19 | 3 | 22 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiovascular Diseases" by people in Profiles.
-
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
-
Measuring Hypothyroidism Disease Control Using a TSH-based "Time-in-range". J Clin Endocrinol Metab. 2026 Jan 21; 111(2):e484-e492.
-
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
-
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 Nov; 10(11):998-1012.
-
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocr Pract. 2026 Jan; 32(1):23-30.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. J Am Heart Assoc. 2025 Aug 05; 14(15):e040217.
-
Living in poverty is associated with gene expression changes in immune cells. Genetics. 2025 Jul 09; 230(3).
-
Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively. J Am Acad Orthop Surg. 2025 Jun 17; 33(16):e971-e978.
-
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Jun 01; 64(6):3434-3443.